Cover Story
By Matthew Bin Han Ong
Moving away from recommendations dating back to 2009, the U.S. Preventive Services Task Force now states that women should start biennial screening for breast cancer at age 40—instead of 50—a change that experts say is based on new, inclusive science.
In Brief
Clinical Roundup
Drugs & Targets
Trending Stories
- Iowa’s Mark Burkard sees a role for data science in bringing clinical trials to rural clinics
The state has the second highest (and rising) cancer rates in the U.S. - At his 25-year “anniversary party,” Pazdur invites Califf and past FDA commissioners to talk about political interference
- How the 2024 elections can impact cancer policy
- GRAIL’s woes raise questions about the prospects of MCDs and standards for their evaluation
- “Less Radical” podcast: Resistance to change, a data scandal
- FDA extends shelf-life for IV fluids in shortage after Hurricane Helene